MERCK
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Announces Oversubscribed $250 Million Growth Financing16.10.2025 16:00:00 CEST | Press release
With backing from Peter Thiel, K5 Global, Jeff Bezos, and Wellington Management, among others, HistoSonics is positioned to expand globally across new clinical applications HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new ownership group and included additional investors Thiel Bio and Founders Fund, among others. The financing will support the ongoing commercial expansion of HistoSonics’ Edison System into new global markets, accelerate new clinical indications throughout the body, and strengthen operational capacity for the next phase of growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016119331/en/ HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics This funding follows the recent $2.25 billion majority stake acquisition of HistoSonics by a consor
The Estée Lauder Companies’ Oevel Manufacturing & Fulfillment Campus Celebrates 60 Years of Excellence and Innovation16.10.2025 15:01:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL), today celebrated the sixtieth anniversary of its Manufacturing & Fulfillment Campus in Oevel, Belgium. Since its opening in 1965, the Oevel Campus has developed into a state-of-the-art manufacturing, fulfillment and biotech hub. Today the campus serves as a cornerstone of the company’s global value chain and is one of its largest manufacturing facilities by volume, annually producing over 100 million prestige beauty products, which are then shipped to more than 100 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016330616/en/ The Estée Lauder Companies celebrates 60th anniversary of its Manufacturing & Fulfillment Campus in Oevel, Belgium “Nearly sixty years ago, my grandparents, Estée and Joseph Lauder, laid the cornerstone of our first facility here in Oevel, establishing what would become a vital part of our global operations,” said William P. Lauder, Chair, Board of
New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub16.10.2025 15:00:00 CEST | Press release
The Health & Pharma Solutions facility offers state-of-the-art laboratory and training rooms for customers Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, today, celebrates the grand opening of its dedicated Health & Pharma Solutions Innovation Center in São Paulo, Brazil. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016102423/en/ Credits to Roquette Located in Barueri, near São Paulo’s city center, the state-of-the-art facility represents a multi-million-dollar investment and reinforces Roquette’s commitment as the pharmaceutical industry’s go-to partner for the development of drug delivery solutions that contribute to life-saving therapies. The center will enable scientific experts to leverage advanced tools, technologies, and expertise to deliver tailored solutions to customers. “Roquette’s new Pharmaceutical Innovation Center in São
Global Study Finds Most SAP Customers Favor Multi-Vendor Composable ERP for Faster Innovation, Including AI16.10.2025 15:00:00 CEST | Press release
Organizations using composable architectures with third-party support achieve above-average performance 83% of the time versus 27% for traditional approaches Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced research findings around the SAP roadmap. In an in-depth study and interactive interview of 455 IT and business leaders, SAP customers voiced concerns over the push toward subscription-based S/4HANA and shared strategies business leaders are adopting to drive innovation and growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016604661/en/ Global Study Finds Most SAP Customers Favor Multi-Vendor Composable ERP for Faster Innovation, Including AI Data revealed that while nearly all SAP customers surveyed are finding it difficult to
Valorem Reply, Microsoft and ITF Bring Real-time AI Analytics to the Billie Jean King Cup by Gainbridge16.10.2025 14:03:00 CEST | Press release
Valorem Reply, the Reply Group company specializing in Microsoft technologies and AI-driven, cloud-native solutions, in collaboration with Microsoft and the International Tennis Federation (ITF), has developed Match Insights, an AI-drivenreal-time analytics application. The solution brings real-time artificial intelligence analytics to the Billie Jean King Cup by Gainbridge, the world’s premier international women’s team tennis competition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016627733/en/ Deployed on Microsoft Surface devices, Match Insights combines mobility and reliability, giving teams access to live insights not only courtside but also in the locker room or off-site. As one of the few elite tournaments that permits on-court coaching, the Billie Jean King Cup presents unique demands for instant, precision-driven tactical decisions. In this environment, even the smallest variations in serve response time or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom